Stenoparib CAS: 1140964-99-3 E-7449

An experimental small-molecule medication known as stenoparib (CAS: 1140964-99-3) is categorized as a PARP (poly ADP-ribose polymerase) inhibitor. Its potential effectiveness in treating a variety of malignancies and viral infections, including COVID-19, has drawn interest from oncologists and virologists. Stenoparib's chemical characteristics, possible side effects, mode of action, safety profile, and other pertinent information are all covered in length in this page.

Comparable Competitive Items
Olaparib (CAS: 763113-22-0) is a PARP inhibitor that is often used in cancer.
Rucaparib is another PARP inhibitor that is used to treat cancer (CAS: 459868-92-9).
A comparable medication that has been authorized for ovarian cancer is niraparib (CAS: 1038915-60-4).
For breast cancer, talazoparib (CAS: 111072-31-2) is an efficient PARP inhibitor.
Veliparib (CAS: 912444-00-9) is an additional PARP inhibitor in research.

Advantages of Stenoparib for Health
Potential Anti-Cancer Activity: Stenoparib causes apoptosis by preventing cancer cells from repairing damaged DNA.
Potential Antiviral Properties: Studies indicate that it may prevent the spread of viruses, especially SARS-CoV-2.
Increasing the Efficacy of Chemotherapy and Radiotherapy Stenoparib may improve the efficacy of conventional cancer therapies by blocking DNA repair.

Possible Impacts
Stenoparib inhibits DNA repair mechanisms by targeting PARP enzymes, which lowers the lifespan of tumor cells.
Possible Antiviral Action: In certain illnesses, this may aid in preventing the spread of viruses.
When it comes to cancers with BRCA1/2 mutations, selective cytotoxicity works better.
Immunomodulatory Effects: May alter the immune system's response to viral and cancerous diseases.

Action Mechanism
The way stenoparib works is by specifically blocking PARP enzymes, which are necessary for fixing single-strand DNA breaks. These breaks eventually develop into double-strand breaks if they are not repaired, which causes genomic instability and ultimately cell death, especially in cancer cells that have BRCA mutations. Furthermore, new research indicates that it may have antiviral properties by disrupting the processes that allow viruses to replicate.

Security
In both preclinical and clinical trials, stenoparib has typically been well tolerated. Safety statistics are still being looked upon, however. Hematological toxicity and gastrointestinal disorders are the main issues. To properly evaluate any dangers, long-term safety studies are required.

A promising experimental PARP inhibitor, stenoparib (CAS: 1140964-99-3) may find use in antiviral therapy and cancer treatment. It is especially helpful in cancers with BRCA mutations because of its capacity to target DNA repair pathways. Furthermore, early research indicates that it could be useful in the fight against viral diseases like COVID-19. To ascertain its complete therapeutic potential, safety profile, and ideal dose regimens, further clinical study is necessary. Before thinking about its clinical use, medical practitioners should keep an eye on continuing research and new data because of its present stage of development.

Additionally, People Inquire About Stenoparib (PAA)

1. What is the purpose of stenoparib?

The main use of stenoparib is as a PARP inhibitor to treat cancer, especially BRCA-mutated malignancies. It is being investigated as a therapy for SARS-CoV-2 and other viral diseases and also has possible antiviral qualities.

2. What is the difference between Stenoparib and other PARP inhibitors?

Although it is still in the early stage, stenoparib is comparable to other PARP inhibitors such as olaparib and rucaparib. Though further study is required, its special qualities could make it more beneficial in certain situations, especially for viral infections.

3. Is Stenoparib authorized by the FDA?

No, the FDA has not yet approved stenoparib for any purposes, and it is currently undergoing clinical testing.

4. What adverse effects might Stenoparib cause?

Leukopenia, anemia, tiredness, and nausea are typical adverse effects. Similar medications in this family have been linked to more serious side effects, including bone marrow suppression and myelodysplastic syndrome.

5. Can COVID-19 be treated with stenoparib?

Although research is still in progress, preliminary findings indicate that Stenoparib may prevent the spread of viruses. It is not currently authorized to treat COVID-19, however, and further research is required to confirm its effectiveness.

6. How does one give stenoparib?

In clinical studies, stenoparib is usually taken orally, and dosage is modified according on patient response and tolerability.

7. Does Stenoparib have any contraindications?

Yes, pregnancy, severe hepatic or renal impairment, hypersensitivity to PARP inhibitors, and significant bone marrow suppression are among the contraindications.

8. Are there any drug interactions with stenoparib?

Indeed, its effectiveness and toxicity may be impacted by interactions with other DNA-damaging substances, chemotherapeutic medications, and certain antivirals. Before using, it is recommended to speak with a healthcare provider.